BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 16758423)

  • 1. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study.
    Kohli R; Lo Y; Homel P; Flanigan TP; Gardner LI; Howard AA; Rompalo AM; Moskaleva G; Schuman P; Schoenbaum EE;
    Clin Infect Dis; 2006 Jul; 43(1):90-8. PubMed ID: 16758423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
    Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
    Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection.
    Sullivan JH; Moore RD; Keruly JC; Chaisson RE
    Am J Respir Crit Care Med; 2000 Jul; 162(1):64-7. PubMed ID: 10903221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of Pneumocystis carinii and community-acquired pneumonia with tobacco use in HIV disease.
    Miguez-Burbano MJ; Ashkin D; Rodriguez A; Duncan R; Pitchenik A; Quintero N; Flores M; Shor-Posner G
    Int J Infect Dis; 2005 Jul; 9(4):208-17. PubMed ID: 15916913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007.
    Bénard A; Mercié P; Alioum A; Bonnet F; Lazaro E; Dupon M; Neau D; Dabis F; Chêne G;
    PLoS One; 2010 Jan; 5(1):e8896. PubMed ID: 20126646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group.
    Hirschtick RE; Glassroth J; Jordan MC; Wilcosky TC; Wallace JM; Kvale PA; Markowitz N; Rosen MJ; Mangura BT; Hopewell PC
    N Engl J Med; 1995 Sep; 333(13):845-51. PubMed ID: 7651475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.
    Madeddu G; Porqueddu EM; Cambosu F; Saba F; Fois AG; Pirina P; Mura MS
    Infection; 2008 Jun; 36(3):231-6. PubMed ID: 18463787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blunted humoral response to influenza vaccination in patients exposed to zidovudine plus trimethoprim-sulfamethoxazole.
    Feola DJ; Garvy BA; Rapp RP; Thornton AC
    Pharmacotherapy; 2007 Jul; 27(7):937-47. PubMed ID: 17594199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators.
    Tumbarello M; Tacconelli E; de Gaetano K; Ardito F; Pirronti T; Cauda R; Ortona L
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 May; 18(1):39-45. PubMed ID: 9593456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth of infants born to HIV-infected women in South Africa according to maternal and infant characteristics.
    Venkatesh KK; Lurie MN; Triche EW; De Bruyn G; Harwell JI; McGarvey ST; Gray GE
    Trop Med Int Health; 2010 Nov; 15(11):1364-74. PubMed ID: 20955499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.